Clinical value of CEUS with tumour marker monitoring in evaluating the prognosis of HCC after MWA.

IF 2.5 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in medical sciences Pub Date : 2025-01-02 DOI:10.1016/j.advms.2025.01.001

Qiang Guo, Yang Yu, Ruyun Ye, Zhiliang Huang, Tingting Shi

{"title":"Clinical value of CEUS with tumour marker monitoring in evaluating the prognosis of HCC after MWA.","authors":"Qiang Guo, Yang Yu, Ruyun Ye, Zhiliang Huang, Tingting Shi","doi":"10.1016/j.advms.2025.01.001","DOIUrl":null,"url":null,"abstract":"Purpose: This study aims to evaluate the prognostic value of contrast-enhanced ultrasound (CEUS) combined with tumour markers in patients with hepatocellular carcinoma (HCC) undergoing microwave ablation (MWA).Methods: MWA patients with HCC were divided into good prognosis (n = 75) and poor prognosis (n = 69) groups. The levels of alpha-fetoprotein (AFP), carbohydrate antigen (CA19-9), and carcinoembryonic antigen (CEA) before and after MWA were analysed using an independent sample t-test. The correlation between prognosis, ablation lesion area, and tumour marker levels were analysed by Pearson's correlation. The diagnostic power of the ablation lesion area combined with tumour marker levels for the prognosis of patients with MWA was analysed using receiver operating characteristic (ROC) curves.Results: The levels of AFP, CA19-9, and CEA in the good prognosis group were significantly lower than those in the poor prognosis group (all P < 0.001). The levels of all tumour markers were significantly negatively correlated with the prognosis of patients who underwent MWA (all r < 0, P < 0.001) and positively correlated with the area of tumour-ablated lesions (r > 0, P < 0.001). Moreover, the diagnostic efficacy of CEUS combined with tumour markers for the prognosis of patients who underwent MWA was significantly higher than that of either single diagnostic modality.Conclusions: CEUS combined with tumour marker monitoring can effectively improve the accuracy of prognostic diagnosis in patients with MWA and provide a reference for timely and reasonable treatment and therapeutic evaluation.","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":" ","pages":"79-85"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.advms.2025.01.001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aims to evaluate the prognostic value of contrast-enhanced ultrasound (CEUS) combined with tumour markers in patients with hepatocellular carcinoma (HCC) undergoing microwave ablation (MWA).

Methods: MWA patients with HCC were divided into good prognosis (n = 75) and poor prognosis (n = 69) groups. The levels of alpha-fetoprotein (AFP), carbohydrate antigen (CA19-9), and carcinoembryonic antigen (CEA) before and after MWA were analysed using an independent sample t-test. The correlation between prognosis, ablation lesion area, and tumour marker levels were analysed by Pearson's correlation. The diagnostic power of the ablation lesion area combined with tumour marker levels for the prognosis of patients with MWA was analysed using receiver operating characteristic (ROC) curves.

Results: The levels of AFP, CA19-9, and CEA in the good prognosis group were significantly lower than those in the poor prognosis group (all P < 0.001). The levels of all tumour markers were significantly negatively correlated with the prognosis of patients who underwent MWA (all r < 0, P < 0.001) and positively correlated with the area of tumour-ablated lesions (r > 0, P < 0.001). Moreover, the diagnostic efficacy of CEUS combined with tumour markers for the prognosis of patients who underwent MWA was significantly higher than that of either single diagnostic modality.

Conclusions: CEUS combined with tumour marker monitoring can effectively improve the accuracy of prognostic diagnosis in patients with MWA and provide a reference for timely and reasonable treatment and therapeutic evaluation.

查看原文本刊更多论文

超声造影联合肿瘤标志物监测对肝癌MWA术后预后评价的临床价值。

目的：本研究旨在评价超声造影（CEUS）联合肿瘤标志物在肝细胞癌（HCC）微波消融（MWA）患者中的预后价值。方法：将MWA合并HCC患者分为预后良好组（n = 75）和预后不良组（n = 69）。采用独立样本t检验分析MWA前后甲胎蛋白（AFP）、碳水化合物抗原（CA19-9）、癌胚抗原（CEA）水平。采用Pearson相关分析预后、消融病灶面积与肿瘤标志物水平的相关性。采用受试者工作特征（ROC）曲线分析消融病灶面积结合肿瘤标志物水平对MWA患者预后的诊断能力。结果：预后良好组患者AFP、CA19-9、CEA水平显著低于预后不良组（P均< 0.001）。所有肿瘤标志物水平与MWA患者预后呈显著负相关（均r < 0, P < 0.001），与肿瘤消融灶面积呈正相关（均r < 0, P < 0.001）。此外，超声造影联合肿瘤标志物对MWA患者预后的诊断效果显著高于任何一种单一诊断方式。结论：超声造影联合肿瘤标志物监测可有效提高MWA患者预后诊断的准确性，为及时合理的治疗和疗效评价提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in medical sciences 医学-医学：研究与实验

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

25 days

期刊介绍： Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.